DD287032A5 - PROCESS FOR PREPARING 3-CARBAMOYL-4-ARYL-1,2-DI-HYDRO-ISOCHINOLIN-1H-ONEN - Google Patents
PROCESS FOR PREPARING 3-CARBAMOYL-4-ARYL-1,2-DI-HYDRO-ISOCHINOLIN-1H-ONEN Download PDFInfo
- Publication number
- DD287032A5 DD287032A5 DD33124689A DD33124689A DD287032A5 DD 287032 A5 DD287032 A5 DD 287032A5 DD 33124689 A DD33124689 A DD 33124689A DD 33124689 A DD33124689 A DD 33124689A DD 287032 A5 DD287032 A5 DD 287032A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- general formula
- aryl
- carbamoyl
- mol
- dihydro
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- GJJVTLOHDLKVFS-UHFFFAOYSA-N 2-benzoylbenzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 GJJVTLOHDLKVFS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000002877 alkyl aryl group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 238000007363 ring formation reaction Methods 0.000 abstract description 4
- 238000007127 saponification reaction Methods 0.000 abstract 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000002082 anti-convulsion Effects 0.000 abstract 1
- 150000002825 nitriles Chemical class 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 239000000155 melt Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 3
- FGTYTUFKXYPTML-UHFFFAOYSA-N 2-benzoylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=CC=C1 FGTYTUFKXYPTML-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- 101000939500 Homo sapiens UBX domain-containing protein 11 Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 102100029645 UBX domain-containing protein 11 Human genes 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- ZIILSLVFVOSHPS-UHFFFAOYSA-N 2-(4-bromobenzoyl)-N-(cyanomethyl)-N-propan-2-ylbenzamide Chemical compound CC(C)N(CC#N)C(=O)c1ccccc1C(=O)c1ccc(Br)cc1 ZIILSLVFVOSHPS-UHFFFAOYSA-N 0.000 description 1
- NONNFIAFWRSPPY-UHFFFAOYSA-N 2-(4-bromobenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(Br)C=C1 NONNFIAFWRSPPY-UHFFFAOYSA-N 0.000 description 1
- FJAZVXUPZQSZKI-UHFFFAOYSA-N 2-(4-fluorobenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(F)C=C1 FJAZVXUPZQSZKI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- WVIVHKYFAGYGGJ-UHFFFAOYSA-N 2-benzoyl-N-(cyanomethyl)-N-propan-2-ylbenzamide Chemical compound CC(C)N(CC#N)C(=O)c1ccccc1C(=O)c1ccccc1 WVIVHKYFAGYGGJ-UHFFFAOYSA-N 0.000 description 1
- KFNZZMLFLXSGEF-UHFFFAOYSA-N 2-benzoyl-N-benzyl-N-(cyanomethyl)benzamide Chemical compound O=C(N(CC#N)Cc1ccccc1)c1ccccc1C(=O)c1ccccc1 KFNZZMLFLXSGEF-UHFFFAOYSA-N 0.000 description 1
- IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008361 aminoacetonitriles Chemical class 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N oxalonitrile Chemical group N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Die Erfindung betrifft ein Verfahren zur Herstellung von * der allgemeinen Formel I durch Cyclokondensation von * zu * und Verseifung der ringgeschlossenen Nitrile. Derartige Verbindungen wirken antikonvulsiv im MES-Test. Formel I{* Cyclokondensation; Natriummethylat; * Verseifung; *}The invention relates to a process for the preparation of * the general formula I by cyclocondensation of * to * and saponification of the ring-closed nitriles. Such compounds have an anticonvulsive effect in the MES test. Formula I {* Cyclocondensation; sodium; * Saponification; *}
Description
wobei R1, R2 und R3 die vorstehend genannte Bedeutung besitzen, isoliert werden und zu Verbindungen der allgemeinen Formel IV cyclokondensiert werden.wherein R 1 , R 2 and R 3 have the abovementioned meaning, are isolated and cyclocondensed to compounds of general formula IV.
3. Verfahren nach Anspruch 1 und 2, dadurch gekennzeichnet, daß der gebildete Chlorwasserstoff durch Basen, vorzugsweise Triethylamin, in einem vorzugsweise aprotischen Lösungsmittel neutralisiert wird.3. The method according to claim 1 and 2, characterized in that the hydrogen chloride formed by bases, preferably triethylamine, is neutralized in a preferably aprotic solvent.
4. Verfahren nach Anspruch 1 und 2, dadurch gekennzeichnet, daß die Cyclisierung vorzugsweise durch Alkanolat unter Zusatz eines Lösungsmittels, vorzugsweise Alkanol, erfolgt.4. The method according to claim 1 and 2, characterized in that the cyclization is preferably carried out by alkoxide with the addition of a solvent, preferably alkanol.
5. Verfahren nach Anspruch 1, dadurch gekennzeichnet, daß die Cyanogruppe in Gegenwart von Laugen verseift wird.5. The method according to claim 1, characterized in that the cyano group is saponified in the presence of alkalis.
6. Verfahren nach Anspruch 1 und 5, dadurch gekennzeichnet, daß vorzugsweise KOH/Isopropanol Verwendung findet.6. The method according to claim 1 and 5, characterized in that preferably KOH / isopropanol is used.
Die Erfindung betrifft ein Verfahren zur Herstellung von G-Carbamoyl^-aryl-i^-dihydro-isochinolin-IH-onen der allgemeinen Formel I. Derartige Verbindungen wirken antikonvulsiv im MES-Test.The invention relates to a process for the preparation of G-carbamoyl-aryl-i-dihydro-isoquinoline-IH-ones of the general formula I. Such compounds have an anticonvulsant effect in the MES test.
CONH2 CONH 2
Verbindungen der allgemeinen Formel I sind weder in der Patent- noch in der chemischen Fachliteratur beschrieben. Von F.Duro, N.A.Santagati und F. Vittorio wird in Il Farmaco, Ed. Sc. 36,400 (1981) die Synthese von 2-Methyl-3-alkoxycarbonyl-4-phenyl-i^-dihydro-isochinolin-IH-on aus dem entsprechenden Isocumarin mitgeteilt. Die aus dem Säurechlorid zugänglichen 2-Methyl-3-(N-alkylcarbamido)-4-phenyl-1,2-dihydro-isochinolin-1H-one wirken lokalanästhetisch.Compounds of general formula I are described neither in the patent nor in the chemical literature. F.Duro, N.A.Santagati and F. Vittorio are working in Il Farmaco, Ed. Sc. 36,400 (1981) reported the synthesis of 2-methyl-3-alkoxycarbonyl-4-phenyl-i-dihydro-isoquinoline-IH-one from the corresponding isocoumarin. The accessible from the acid chloride 2-methyl-3- (N-alkylcarbamido) -4-phenyl-1,2-dihydro-isoquinoline-1H-one act locally anesthetics.
Ziel der Erfindung ist es, derartige Verbindungen aus relativ leicht zugänglichen Ausgangsmaterialien in einfacher Weise und mit hohen Ausbeuten herzustellen.The aim of the invention is to produce such compounds from relatively easily accessible starting materials in a simple manner and with high yields.
Aufgabe der Erfindung ist es, einen technisch anwendbaren Syntheseweg zur Herstellung von 3-Carbamoyl-4-aryl-1,2-dihydroisochinolin-1H-onen der allgemeinen Formel !aufzufinden. Erfindungsgemäß wird die Aufgabezur Darstellung der Verbindung der allgemeinen Formel I,The object of the invention is to find a technically applicable synthesis route for the preparation of 3-carbamoyl-4-aryl-1,2-dihydroisoquinolin-1H-ones of the general formula! According to the invention, the object of preparing the compound of general formula I,
CONH2 CONH 2
wobei R1 - Alkyl, Akarylwhere R 1 is alkyl, akaryl
R' = H, F, Cl, Br, NO, bedeuten, dadurch gelöst, daß Aminoacetonitrile der allgemeinen Formel II,R '= H, F, Cl, Br, NO, in which aminoacetonitriles of the general formula II
,1,1
HN-—-CNHN --- CN
wobei R* die vorstehend genannte Bedeutung besitzt und 2-Benzoyl-benzoesäurechloride der allgemeinen Formel III,where R * has the abovementioned meaning and 2-benzoyl-benzoic acid chlorides of the general formula III,
wobei R2 und R3 die vorstehend genannte Bedeutung besitzen, zur Reaktion gebracht werden und zu 3-Cyano-4-aryl-1,2-dihydroisochinolin-1H-onen der allgemeinen Formel IV,where R 2 and R 3 have the abovementioned meaning, and are converted to 3-cyano-4-aryl-1,2-dihydroisoquinolin-1H-ones of the general formula IV,
IVIV
wobei R1, R2 und R1 die vorstehend genannte Bedeutung besitzen, in Gegenwart von Basen cyclisiert werden und diewherein R 1 , R 2 and R 1 have the abovementioned meaning, are cyclized in the presence of bases and the
wobei R(, R' und R5 die vorstehend genannte Bedeutung besitzen, können isoliert werden und durch Cyclisierung zu IV umge - atzt werden.where R ( , R 'and R 5 have the abovementioned meaning, can be isolated and etched by cyclization to IV.
Die Erfindung soll nachstehend an neun Ausführungsbeispielen näher erläutert werden. 3-Carbamoyl-4-aryl-1,2-dihydro-isochinolin-1H-oneThe invention will be explained in more detail below in nine embodiments. 3-carbamoyl-4-aryl-1,2-dihydro-isoquinoline-1H-one
2-lsopropyl-3-carbamoyl-4-phenyl-1,2-dihydru-isochinolin-1H-on I;2-isopropyl-3-carbamoyl-4-phenyl-1,2-dihydru-isoquinolin-1H-one I;
R1 = CH(CHj)1, R1 = R3 = HR 1 = CH (CHj) 1 , R 1 = R 3 = H
16g (55mMol) 2-lsopropyl-3cyar.o-4-phenyl-1,2-dihydro-isochinolin-1H-on (IV; R1 = CH(CHj),, R2 = R3 « H), 9,5g (27OmMoI)16 g (55 mmol) 2-isopropyl-3-cyano-4-phenyl-1,2-dihydro-isoquinolin-1H-one (IV; R 1 = CH (CHj), R 2 = R 3 H), 9, 5g (27OmMoI)
der Feststoff abgesaugt. Es werden I6,2g (96%) I erhalten. Die Verbindung schmilzt bei 219-22TC.the solid is sucked off. I6.2g (96%) I is obtained. The compound melts at 219-22TC.
2·ΐ5ορΓορνΙ·3·€3Γ03ηιονΙ·(4·(4-ίΙυοΓρΙιβηνΙ))-112-(ϋΙιναΓθ-ΐ5(κ:ΜΙηοΜη-1Η-οη I; R1 = CH(CH3),, R2 = 4-F, R3 = H2 · ΐ5ορΓορνΙ · 3 · € 3Γ03ηιονΙ · (4 · (4-ίΙυοΓρΙιβηνΙ)) - 1 1 2- (ϋΙιναΓθ-ΐ5 (κ: ΜΙηοΜη-1Η-οη I; R 1 = CH (CH 3 ) ,, R 2 = 4-F, R 3 = H
werden 30g (92%) I erhalten. Die Verbindung schmilzt bei 209-2100C.will receive 30g (92%) I. The compound melts at 209-210 0 C.
2-Benzyl-3-carbamoyl-4-phenyl-1,2-dihydro-isochinolin-1H-on I; R1 = Benzyl, R2 = R3 = H2-Benzyl-3-carbamoyl-4-phenyl-1,2-dihydro-isoquinolin-1H-one I; R 1 = benzyl, R 2 = R 3 = H
3-Cyano-4-aryl-1,2-dihydro-isochinolin-1 H-one3-Cyano-4-aryl-1,2-dihydro-isoquinoline-1H-one
2-lsopropyl-3-cyano-4-phenyl-1,2-dihydro-isochinolin-1H-on IV; R1 = CH(CH3),, R1 = R2 = H Im 1-l-Dreihalskolben, versehen mit Rührerund RückflußKühler, werden 90,4 g (0,4 Mol) 2-Benzoyl-benzoesäure (III; R2 = R3 = H) mit 150ml SOCI, versetzt und 0,5Std. bei Raumtemperatur und 1Std. bei einer Badtemperatur von 50°C gerührt. Das überschüssige SOCI, wird unter leichtem Vakuum abdestilliert, der Rückstand in 24OmI CH2CI2 aufgenommen und 39,2g (0,4MoI) N-lsopropyl-aminoacetonitril (II; R' = CH(CH3), und 44,4g (0,44MoI) Triethylamin, gelöst in 160ml CH2CI2, bei Zimmertemperatur zugetropft. Anschließend wird 2Std. unter Rückfluß gekocht. Nach Abkühlen werden 200ml Wasser eingerührt und die Phasen getrennt. Die organische Phase wird nacheinander mit je 100ml verdünnter HCI, NaHCOj-Lsg. sowie Wasser gewaschen und über CaCI, getrocknet. Das Lösungsmittel wird abdestilliert, der Rückstand in 800ml CH3OH aufgenommen, 22g (0,4Mol) NaOCH3 zugegeben und 1 Std. unter Rückfluß gekocht. Nach Abkühlen wird mit 800ml H2O verdünnt, der Feststoff abgetrennt und aus Isopropanol umkristallisiert. Es werden 51,8g (45%) IV erhalten. Die Verbindung schmilzt bei 172-1730C.2-isopropyl-3-cyano-4-phenyl-1,2-dihydroisoquinolin-1H-one IV; R 1 = CH (CH 3 ) ,, R 1 = R 2 = H In the 1 liter three-necked flask equipped with stirrer and reflux condenser, add 90.4 g (0.4 mol) of 2-benzoylbenzoic acid (III; R 2 = R 3 = H) with 150 ml SOCI, and 0.5 hr. at room temperature and 1 h. stirred at a bath temperature of 50 ° C. The excess SOCI, is distilled off under a slight vacuum, the residue taken up in 24OmI CH 2 CI 2 and 39.2 g (0,4MoI) N-isopropyl-aminoacetonitrile (II; R '= CH (CH 3), and 44,4g ( 0.41 mol) Triethylamine, dissolved in 160 ml of CH 2 Cl 2 , is added dropwise at room temperature, followed by refluxing for 2 hours After cooling, 200 ml of water are stirred in and the phases are separated. The solvent is distilled off, the residue is taken up in 800 ml of CH 3 OH, 22 g (0.4 mol) of NaOCH 3 are added and the mixture is refluxed for 1 hour, after cooling with 800 ml of H 2 O. diluted, and the solid collected and recrystallized from isopropanol. There are obtained 51,8g (45%) IV. the compound melts at 172-173 0 C.
2-lsopropyl-3-cyano-(4-(4-fluorphe.;vl))-1,2-dihydro-isochinolin-1H-on IV; R1 = CH(CH3I2, R2 = 4-F, R3 = H2-isopropyl-3-cyano- (4- (4-fluorophenol; vl)) - 1,2-dihydro-isoquinolin-1H-one IV; R 1 = CH (CH 3 I 2 , R 2 = 4-F, R 3 = H
2-Benzyl-3-cyano-4-phenyl-1,2-dihydro-isochinolin-1H-on IV; R1 = Benzyl, R2 = R' = H2-Benzyl-3-cyano-4-phenyl-1,2-dihydroisoquinolin-1H-one IV; R 1 = benzyl, R 2 = R '= H
das Produkt mit 800ml Wasser ausgefällt, abgesaugt, getrocknet und aus Isopropanol umkristallisiert. Es werden 97g (72%) I erhalten. Die Verbindung schmilzt bei 196-198°C.the product was precipitated with 800 ml of water, filtered off, dried and recrystallized from isopropanol. There are 97g (72%) I received. The compound melts at 196-198 ° C.
2-lsopropyl-3-cyano-4-phenyl-6-chlor-1,2-dihydro-isochinolin-1H-on IV; R' = CH(CH3I2, R2 = H, R3 = 6-CI2-isopropyl-3-cyano-4-phenyl-6-chloro-1,2-dihydro-isoquinolin-1H-one IV; R '= CH (CH 3 I 2 , R 2 = H, R 3 = 6-CI
(63%) I erhalten. Die Verbindung schmilzt bei 209-2100C.(63%) I received. The compound melts at 209-210 0 C.
(N-Cyanomethyl-N-alkyl)-(2-benzoyl)-benzamide(N-cyanomethyl-N-alkyl) - (2-benzoyl) benzamide
(N-Cyanomethyl-N-isopropyl)-(2-benzoyl)-benzamid V; R1 = CH(CHj)2, R2 = R3 = H(N-cyanomethyl-N-isopropyl) - (2-benzoyl) -benzamide V; R 1 = CH (CHj) 2 , R 2 = R 3 = H
mit 150ml Thionylchlorid versetzt und 0,5Sld. bei Raumtemperatur und 1 Std. bei einer Badtemperatur von 500C gerührt. Das überschüssige Thionylchlorid wird unter leichtem Vakuum abdestilliert, der Rückstand in 240ml Methylenchlorid aufgenommen und 39,2g (0,4MoI) N-lsopropyl-aminoacetcnitril (II; R1 - CH(CH3),) und 44,4g (0,44MoI) Triethylamin, gelöst in 160mlwith 150ml thionyl chloride and 0.5Sld. at room temperature and 1 hr. At a bath temperature of 50 0 C stirred. The excess thionyl chloride is distilled off under slight vacuum, the residue taken up in 240 ml of methylene chloride and 39.2 g (0.4 mol) of N-isopropyl-aminoacetcnitrile (II; R 1 -CH (CH 3 ),) and 44.4 g (0.44 mol ) Triethylamine, dissolved in 160ml
200ml Wasser eingei 'irt und die Phasen getrennt. Dieorganische Phase wird nacheinander mit je 100ml verd. HCI, NaHCO3-LSg.200ml of water eingei 'irt and the phases separated. The organic phase is successively with 100ml Verd. HCI, NaHCO 3 -LSg.
sowie Wasser gewaschen und mit CaCI, getrocknet. Das Lösungsmittel wird abdestilliert und der Rückstand in 250ml Methanol aufgenommen. Nach einiger Zeit kristallisiert V aus. Es werden 75,5g (62%) erhalten. Die Verbindung schmilzt bei 104-106'C.washed with water and washed with CaCl 2. The solvent is distilled off and the residue taken up in 250 ml of methanol. After some time, V crystallizes out. It will receive 75.5g (62%). The compound melts at 104-106'C.
(N-Cyanomethyl-N-isopropyl)-(2-(4-brombenzoyl))-benzamid V; P.'' = CH(CH3),, R2 = 4-Brom, R3 = H(N-cyanomethyl-N-isopropyl) - (2- (4-bromobenzoyl)) - benzamide V; P. '' = CH (CH 3 ) ,, R 2 = 4-bromo, R 3 = H
Claims (2)
bedeuten, dadurch gekennzeichnet, daß substituierte Aminoactonitrile der allgemeinen Formel II,R 3 = H, F, Cl, Br, NO 2
, characterized in that substituted amino-lactonitriles of the general formula II,
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD33124689A DD287032A5 (en) | 1989-07-28 | 1989-07-28 | PROCESS FOR PREPARING 3-CARBAMOYL-4-ARYL-1,2-DI-HYDRO-ISOCHINOLIN-1H-ONEN |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD33124689A DD287032A5 (en) | 1989-07-28 | 1989-07-28 | PROCESS FOR PREPARING 3-CARBAMOYL-4-ARYL-1,2-DI-HYDRO-ISOCHINOLIN-1H-ONEN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD287032A5 true DD287032A5 (en) | 1991-02-14 |
Family
ID=5611218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD33124689A DD287032A5 (en) | 1989-07-28 | 1989-07-28 | PROCESS FOR PREPARING 3-CARBAMOYL-4-ARYL-1,2-DI-HYDRO-ISOCHINOLIN-1H-ONEN |
Country Status (1)
| Country | Link |
|---|---|
| DD (1) | DD287032A5 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002062764A1 (en) * | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
| EP1667981A4 (en) * | 2003-09-23 | 2008-08-13 | Merck & Co Inc | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS |
| US7902193B2 (en) | 2005-10-19 | 2011-03-08 | Maybridge Limited | Phthalazinone derivatives |
| US7981890B2 (en) | 2007-09-14 | 2011-07-19 | Astrazeneca Ab | Phthalazinone derivatives |
| US8129380B2 (en) | 2008-01-23 | 2012-03-06 | Astrazeneca Ab | Phthalazinone derivatives |
| US8183369B2 (en) | 2007-10-17 | 2012-05-22 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-I-carbonyl) -4 -fluoro-benzyl] -2H-phthalaz in-1-one |
| US8475842B2 (en) | 2008-10-07 | 2013-07-02 | Astrazeneca Ab | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
| US8912187B2 (en) | 2003-03-12 | 2014-12-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
-
1989
- 1989-07-28 DD DD33124689A patent/DD287032A5/en not_active IP Right Cessation
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002062764A1 (en) * | 2001-02-02 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Fused heterocyclic compounds |
| US8912187B2 (en) | 2003-03-12 | 2014-12-16 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US9566276B2 (en) | 2003-03-12 | 2017-02-14 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US9169235B2 (en) | 2003-03-12 | 2015-10-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| EP1667981A4 (en) * | 2003-09-23 | 2008-08-13 | Merck & Co Inc | ISOQUINOLINE POTASSIUM CHANNEL INHIBITORS |
| AU2004276268B2 (en) * | 2003-09-23 | 2009-01-29 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
| US7902193B2 (en) | 2005-10-19 | 2011-03-08 | Maybridge Limited | Phthalazinone derivatives |
| US7981890B2 (en) | 2007-09-14 | 2011-07-19 | Astrazeneca Ab | Phthalazinone derivatives |
| US8183369B2 (en) | 2007-10-17 | 2012-05-22 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-I-carbonyl) -4 -fluoro-benzyl] -2H-phthalaz in-1-one |
| US8129380B2 (en) | 2008-01-23 | 2012-03-06 | Astrazeneca Ab | Phthalazinone derivatives |
| US8475842B2 (en) | 2008-10-07 | 2013-07-02 | Astrazeneca Ab | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
| US11633396B2 (en) | 2008-10-07 | 2023-04-25 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one |
| US11975001B2 (en) | 2008-10-07 | 2024-05-07 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
| US12048695B2 (en) | 2008-10-07 | 2024-07-30 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
| US12144810B1 (en) | 2008-10-07 | 2024-11-19 | Kudos Pharmaceuticals Limited | Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69226822T2 (en) | Diastereomeric salt of optically active quinoline mevalonic acid | |
| CH643545A5 (en) | METHOD FOR PRODUCING CHIRAL SUBSTITUTED 2-IMIDAZOLIN-5-ONE AND THE USE THEREOF. | |
| EP1009731B1 (en) | Method for producing aryloligoamines | |
| DD287032A5 (en) | PROCESS FOR PREPARING 3-CARBAMOYL-4-ARYL-1,2-DI-HYDRO-ISOCHINOLIN-1H-ONEN | |
| DE2732213A1 (en) | DERIVATIVES OF THE CYCLOPROPANCARBONIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND THEIR USE AS INTERMEDIATE PRODUCTS IN THE MANUFACTURING OF INSECTICIDES | |
| EP0216324B1 (en) | 4-alkoxy-3-pyrrolin-2-one-1-yl-acetic acid alkyl and benzyl esters and their preparation | |
| AT391866B (en) | METHOD FOR PRODUCING NEW S-TRIAZOLO (1,5-A) PYRIMIDINE | |
| DE19706396A1 (en) | Process for the preparation of 3- (l-hydroxiphenyl-l-alkoximinomethyl) dioxazines | |
| DE2406198C2 (en) | Process for the preparation of new 2-amino-6-dialkylamino-dihydropyridines | |
| DD247217A5 (en) | PROCESS FOR PREPARING 2,6-DIMETHYL-4- (3'-NITROPHENYL) -1,4-DIHYDROPYRIDINE-3,5-DICARBONE ACID-3 BETA (N-BENZYL-N-METHYLAMINO) ETHETYLENE-5-METHYL ESTER AND THE HYDROCHLORIDE SALT | |
| DE1935404C3 (en) | Process for the manufacture of quinazolines | |
| EP0362350A1 (en) | Process for producing 5-member nitrogen-containing hetero-aromatic compounds | |
| Lewis et al. | 2-Amino-5, 6-dihydroxyindan-2-carboxylic acid. A potential hypotensive agent | |
| EP0184981A1 (en) | Pyrrolinones and their intermediate products | |
| DE1545856A1 (en) | Process for the preparation of basic substituted derivatives of 5,6-dihydro-dibenz- [b, e] -azepine-6,11-dione-11-oxime | |
| DE3729094C2 (en) | ||
| DE3625269C2 (en) | ||
| EP0694534A1 (en) | 3-Substituted quinoline-5-carboxylic acid derivatives and processes for their preparation | |
| DE4408083C1 (en) | Process for the preparation of 4-fluoroalkoxycinnamonitriles | |
| US3262937A (en) | Benzyl piperidyl ketones | |
| EP0056938B1 (en) | Process for the preparation of 3,6-disubstituted 4-amino-1,2,4-triazin-5-ones | |
| DE3815046A1 (en) | 3-CHLORINE-2-METHYLPHENETHYLAMINE DERIVATIVES | |
| DE69700122T2 (en) | Process for the preparation of dithiocarbonimide derivatives | |
| DE3423105A1 (en) | METHOD FOR PRODUCING OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE | |
| CH628015A5 (en) | METHOD FOR DECARBALCOXYLATING CARBONIC ACID ESTERS. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |